Assenagon Asset Management S.A. Grows Stock Position in Emergent BioSolutions Inc. (NYSE:EBS)

Assenagon Asset Management S.A. raised its holdings in Emergent BioSolutions Inc. (NYSE:EBS) by 3.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 766,537 shares of the biopharmaceutical company’s stock after buying an additional 24,985 shares during the quarter. Assenagon Asset Management S.A. owned approximately 1.41% of Emergent BioSolutions worth $7,328,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Vanguard Personalized Indexing Management LLC purchased a new position in Emergent BioSolutions during the second quarter worth approximately $93,000. Stifel Financial Corp purchased a new position in shares of Emergent BioSolutions in the 3rd quarter worth about $96,000. Morse Asset Management Inc acquired a new position in shares of Emergent BioSolutions in the 2nd quarter valued at about $97,000. FORA Capital LLC purchased a new stake in shares of Emergent BioSolutions during the 3rd quarter worth about $103,000. Finally, Landscape Capital Management L.L.C. acquired a new stake in Emergent BioSolutions during the 3rd quarter worth approximately $141,000. Institutional investors and hedge funds own 78.40% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the stock. Benchmark lifted their price target on shares of Emergent BioSolutions from $8.00 to $12.00 and gave the company a “buy” rating in a research report on Thursday, November 7th. HC Wainwright reaffirmed a “buy” rating and set a $15.00 price target on shares of Emergent BioSolutions in a research report on Friday, January 10th. Finally, StockNews.com raised Emergent BioSolutions from a “hold” rating to a “buy” rating in a research report on Tuesday, January 14th.

Emergent BioSolutions Stock Performance

Emergent BioSolutions stock opened at $9.91 on Monday. Emergent BioSolutions Inc. has a 12-month low of $1.42 and a 12-month high of $15.10. The company has a debt-to-equity ratio of 1.30, a current ratio of 2.88 and a quick ratio of 1.47. The company has a market capitalization of $536.69 million, a price-to-earnings ratio of -2.42 and a beta of 1.60. The firm’s fifty day moving average price is $9.31 and its 200 day moving average price is $9.23.

About Emergent BioSolutions

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.